QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases ...Middle East

PR Newswire - News
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round Financing supports clinical activities for Company's two lead programs in ALS and pipeline development CAMBRIDGE, Mass., March 9, 2023 /PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company...

Hence then, the article about quralis closes 88 million series b financing to advance precision medicines for neurodegenerative diseases was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases )

Apple Storegoogle play

Last updated :

Also on site :